company background image


Last Price


Market Cap







09 Aug, 2022


Company Financials
LIDDS fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

LIDDS Stock Overview

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden.

LIDDS AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LIDDS
Historical stock prices
Current Share Pricekr6.86
52 Week Highkr15.66
52 Week Lowkr5.70
1 Month Change-2.00%
3 Month Change-7.80%
1 Year Change-54.14%
3 Year Change-61.02%
5 Year Change-40.61%
Change since IPO-37.64%

Recent News & Updates

May 26
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

LIDDSSE BiotechsSE Market

Return vs Industry: LIDDS underperformed the Swedish Biotechs industry which returned -22.1% over the past year.

Return vs Market: LIDDS underperformed the Swedish Market which returned -22% over the past year.

Price Volatility

Is LIDDS's price volatile compared to industry and market?
LIDDS volatility
LIDDS Average Weekly Movement9.2%
Biotechs Industry Average Movement9.7%
Market Average Movement7.3%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.6%

Stable Share Price: LIDDS is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LIDDS's weekly volatility (9%) has been stable over the past year.

About the Company

n/a6Nina Herne

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations.

LIDDS AB (publ) Fundamentals Summary

How do LIDDS's earnings and revenue compare to its market cap?
LIDDS fundamental statistics
Market Capkr238.31m
Earnings (TTM)-kr36.24m
Revenue (TTM)kr3.51m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LIDDS income statement (TTM)
Cost of Revenuekr26.70m
Gross Profit-kr23.20m
Other Expenseskr13.04m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-1.04
Gross Margin-661.61%
Net Profit Margin-1,033.54%
Debt/Equity Ratio0.0%

How did LIDDS perform over the long term?

See historical performance and comparison